


Eritoran tetrasodium

Cat. No.:	HY-105070A
CAS No.:	185954-98-7
Molecular Formula:	C ₆₆ H ₁₂₂ N ₂ Na ₄ O ₁₉ P ₂
Molecular Weight:	1401.58
Target:	EBV; Toll-like Receptor (TLR)
Pathway:	Anti-infection; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Eritoran tetrasodium (E5564) is a Toll-like receptor 4 (TLR4) antagonist. Eritoran tetrasodium protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran tetrasodium decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran tetrasodium inhibits pathogenesis of filovirus infection. Eritoran tetrasodium has anti-inflammatory activity ^{[1][2]} .								
In Vivo	<p>Eritoran tetrasodium (233 µg/mouse; i.p.; 10 days) protects mouse from EBOV lethal infection, results 70% survived until the end of the study^[1].</p> <p>Eritoran tetrasodium (2 µL of 1.1 mg/mL, corneal infusion) inhibits LPS (HY-D1056) -induced corneal inflammation in mice^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6J mice challenged with lethal EBOV^[1]</td> </tr> <tr> <td>Dosage:</td> <td>233 µg/mouse</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 10 days</td> </tr> <tr> <td>Result:</td> <td> Reduced granulocytosis and results in a higher percentage of activated CD11b+ Ly6G/Ly6C+ neutrophils. Dramatically reduced the levels of IFN-γ-secreting CD8+ and CD4+ T cells and IL-17A-secreting CD4+ T cells. </td> </tr> </table>	Animal Model:	C57BL/6J mice challenged with lethal EBOV ^[1]	Dosage:	233 µg/mouse	Administration:	Intraperitoneal injection; 10 days	Result:	Reduced granulocytosis and results in a higher percentage of activated CD11b+ Ly6G/Ly6C+ neutrophils. Dramatically reduced the levels of IFN-γ-secreting CD8+ and CD4+ T cells and IL-17A-secreting CD4+ T cells.
Animal Model:	C57BL/6J mice challenged with lethal EBOV ^[1]								
Dosage:	233 µg/mouse								
Administration:	Intraperitoneal injection; 10 days								
Result:	Reduced granulocytosis and results in a higher percentage of activated CD11b+ Ly6G/Ly6C+ neutrophils. Dramatically reduced the levels of IFN-γ-secreting CD8+ and CD4+ T cells and IL-17A-secreting CD4+ T cells.								

REFERENCES

[1]. Younan P, et al. The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge. *mBio*. 2017 Apr 25;8(2):e00226-17

[2]. Sun Y, et al. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564). *Invest Ophthalmol Vis Sci*. 2009 Mar;50(3):1247-54.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA